Sinda-Bio has published its 2023 Annual Report, covering the fiscal year ended 31 December 2023. The report shows that Sinda Biologics is a company focused on the field of biopharmaceuticals such as oncology, cardiovascular and metabolic diseases, autoimmune diseases and ophthalmology. Since its inception in 2011, it has established more than 30 international partners including Lai, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Centers Strategic Collaboration. The product pipeline includes 36 products in research, 10 approved marketed products, 3 products under NMPA audit, 5 molecules entering Phase III or pivotal clinical trials, and 18 in the early clinical phase. Due to the rapid growth of product sales revenue, an increase in gross profit margin of gross profit and a decrease in the proportion of total revenue from...Show More

Sinda-Bio has published its 2023 Annual Report, covering the fiscal year ended 31 December 2023. The report shows that Sinda Biologics is a company focused on the field of biopharmaceuticals such as oncology, cardiovascular and metabolic diseases, autoimmune diseases and ophthalmology. Since its inception in 2011, it has established more than 30 international partners including Lai, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Centers Strategic Collaboration. The product pipeline includes 36 products in research, 10 approved marketed products, 3 products under NMPA audit, 5 molecules entering Phase III or pivotal clinical trials, and 18 in the early clinical phase. Due to the rapid growth of product sales revenue, an increase in gross profit margin of gross profit and a decrease in the proportion of total revenue from sales, marketing, administrative and other expenses, the Company's fiscal performance improved in 2023, reaching RMB6206.1, up 36.2% year-on-year, and product revenue of 5728.3 yuan The yuan, up 38.4% year-on-year, and LBITDA decreased 73.0% to 600.1 yuan renminbi. The financial situation of the company is stable, cash and short-term financial assets are approximately 10969.6 RMB. In 2023, SindaBio will expand its portfolio of listed products to 10, of which two innovative products Fokosu® (Igoleon monoclonal injection) and Xinbile® (Toralexi monoclonal injection) will be available in China. The company continues to focus on innovative cancer therapies and strategically focuses on multiple therapeutic areas with high clinical demand. With its commitment to high quality production standards and corporate social responsibility, Sinda Biologics has been upgraded to 'A' level in the MSCI ESG rating in 2023, leading the Chinese pharmaceutical industry.